Friday, October 21, 2022
Genetic Engineering and Biotechnology News
Eli Lilly has agreed to acquire Akouos for up to $610 million, in a deal intended to expand the buyer’s presence in gene therapy with a focus on treating inner ear disorders. Akouos, which has licensed key technology from the University of Iowa, develops targeted adeno-associated viral (AAV) vector-based gene therapies for conditions that include sensorineural hearing loss, integrating expertise in otology and inner ear drug delivery, as well as gene therapy.